Conditional Survival Estimates Improve Over 5 Years for Melanoma Survivors with Node-Positive Disease

Bowles, Tawnya L.; Xing, Yan; Hu, Chung Yuan; Mungovan, Kristi S.; Askew, Robert L.; Chang, George J.; Gershenwald, Jeffrey E.; Lee, Jeffrey E.; Mansfield, Paul F.; Ross, Merrick I.; Cormier, Janice N.

doi:10.1245/s10434-010-1051-y

Cited by 29 publications

(28 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, with time, the conditional survival estimates demonstrate that the age gradient, or negative impact of age, narrows with time in patients with localized and regional disease. Prior studies have used age 50 as a binomial cut point, obscuring the effects of more advanced age at diagnosis [18–19]. One European study did demonstrate an improvement in conditional survival estimates by age, with a narrowing of the age gradient for melanoma patients, but this was not further analyzed by stage [12].…”

Section: Discussionmentioning

confidence: 99%

Implications of age and conditional survival estimates for patients with melanoma

Banerjee¹,

Wancata²,

Muenz³

et al. 2016

Melanoma Research

View full text Add to dashboard Cite

Objective Overall cancer incidence is decreasing while melanoma cases increase. Conditional survival estimates offer a more accurate prognosis for patients as they survive past diagnosis. It is unknown the effect age and stage has on a melanoma patient’s conditional survival estimate. Methods Surveillance, Epidemiology, End Results (SEER) data was utilized, identifying new diagnosis cutaneous melanoma patients (N=95,041), from 1998–2005, with up to 12 year follow up. Estimates of disease-specific survival by stage and age were determined by Cox regression and transformed to estimate conditional five-year survival. Results Localized melanoma patients have an excellent five-year survival at diagnosis and subsequent years. For patients with localized and regional disease, an age effect is present for disease-specific mortality when comparing older patients (70–79 years) to younger patients (<30 years): hazard ratio (HR) for mortality 3.79 (95% confidence interval (CI) 3.01–4.84) and HR 2.36 (95% CI 1.93–2.91), respectively. No age effect difference is observed in disease-specific survival for advanced disease: HR 1.14 (95% CI 0.87–1.53). Over time conditional survival estimates improve for older patients with localized and regional disease. This improvement is not seen in distant disease nor is the age gradient. Conclusions Disease-specific mortality and conditional survival for patients with localized and regional melanoma is initially impacted by older age with effects dissipating over time. Age does not affect survival in patients with advanced disease. Understanding the conditional five-year disease-specific survival of melanoma based on age and stage can help patients and physicians, informing decision making about treatment and surveillance.

show abstract

Section: Discussionmentioning

confidence: 99%

Implications of age and conditional survival estimates for patients with melanoma

Banerjee¹,

Wancata²,

Muenz³

et al. 2016

Melanoma Research

View full text Add to dashboard Cite

show abstract

“…For example, overall 5-year conditional survival estimates for patients with stage I melanoma do not significantly change in the first 5 years after diagnosis [23][24][25]. In contrast, for patients with stage III and even more notably for patients with stage IV melanoma, estimates of 5-year conditional survival increase in each year for at least the first 5 years following the initial diagnosis of stage III or IV melanoma [23][24][25].…”

Section: American Joint Committee On Cancer (Ajcc) Melanoma Staging Smentioning

confidence: 97%

Cutaneous melanoma: A model to study cancer metastasis

Leong

Gershenwald

Soong

et al. 2011

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

Nodal status in melanoma is a critically important prognostic factor for patient outcome. The survival rate drops to <10% when melanoma has spread beyond the regional lymph nodes and includes visceral involvement. In general, the process of melanoma metastasis is progressive in that dissemination of melanoma from the primary site to the regional lymph nodes occurs prior to systemic disease. The goal of this review article is to describe melanoma as a clinical model to study cancer metastasis. A future challenge is to develop a molecular taxonomy to subgroup melanoma patients at various stages of tumor progression for more accurate targeted treatment.

show abstract

“…In contrast, patients with benign nodal nevus aggregates have been shown to present with a 5 year survival similar to that of patients who had no positive findings on sentinel lymph node biopsies [7], [8]. Thus, the differentiation between the nodal nevi and metastatic lymph nodes has a profound effect on the prognosis of the patient, as the recognition of the differences is important to avoid misdiagnosis and provide adequate therapy options [7], [8], [9].…”

Section: Introductionmentioning

confidence: 99%

Capsular nevus versus metastatic malignant melanoma – a diagnostic dilemma

Davis

Patil

Aydin

et al. 2016

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

HighlightsThere are many morphologic guidelines to recognize nodal nevus cells, but there are some cases where the prediction of behavior of certain cells may not be accurate solely based on histopathological findings.Advanced histopathological techniques including implementing multiple markers should be employed in scenarios where distinguishing metastatic melanocytes from capsular nevi prove to be difficult.We strongly encourage obtaining a second opinion from a second histopathologist, preferably at a high volume center in cases where benign and malignant distinctions are difficult to make.

show abstract

Conditional Survival Estimates Improve Over 5 Years for Melanoma Survivors with Node-Positive Disease

Cited by 29 publications

References 26 publications

Implications of age and conditional survival estimates for patients with melanoma

Implications of age and conditional survival estimates for patients with melanoma

Cutaneous melanoma: A model to study cancer metastasis

Capsular nevus versus metastatic malignant melanoma – a diagnostic dilemma

Contact Info

Product

Resources

About